Compare VVOS & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | TRIB |
|---|---|---|
| Founded | 2016 | 1992 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1M | 14.0M |
| IPO Year | 2020 | 1996 |
| Metric | VVOS | TRIB |
|---|---|---|
| Price | $1.33 | $0.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | 87.8K | ★ 129.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,031,000.00 | N/A |
| Revenue This Year | $31.42 | $13.51 |
| Revenue Next Year | $49.82 | $13.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.91 | N/A |
| 52 Week Low | $1.28 | $0.48 |
| 52 Week High | $7.40 | $3.44 |
| Indicator | VVOS | TRIB |
|---|---|---|
| Relative Strength Index (RSI) | 38.14 | 42.26 |
| Support Level | N/A | $0.65 |
| Resistance Level | $1.88 | $0.70 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 18.53 | 44.37 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.